{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-001110","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2025-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.268041+00:00","generated_at":"2026-05-24T03:06:19.236865+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Entera Bio reports FY2024 net loss of $9.5M; cash $21M as of March 28, 2025","bullets":["Net loss $9.5M ($0.25 per share) vs $8.9M ($0.31 per share) in FY2023.","Cash and equivalents $8.7M at Dec 31, 2024; $21M as of March 28, 2025 after new investments.","R&D expenses flat at $4.5M; G&A increased to $5.1M from $4.4M.","Entera and OPKO entered oral GLP-1/Glucagon license agreement; IND filing expected in 2025.","EB613 Phase 3 study planned pending FDA surrogate endpoint qualification; SABRE ruling awaited."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-001110","json":"https://secwatch.observer/filing/0001178913-25-001110.json","markdown":"https://secwatch.observer/filing/0001178913-25-001110.md","text":"https://secwatch.observer/filing/0001178913-25-001110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891325001110/0001178913-25-001110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891325001110/zk2532935.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:06:19.236865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}